Gbola Amusa
Stock Analyst at Chardan Capital
(1.98)
# 2,841
Out of 4,789 analysts
61
Total ratings
40%
Success rate
2.87%
Average return
Main Sectors:
Stocks Rated by Gbola Amusa
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $200 → $50 | $3.83 | +1,205.48% | 2 | Apr 29, 2021 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $60 → $68 | $1.27 | +5,235.97% | 3 | Apr 13, 2021 | |
| FBRX Forte Biosciences | Maintains: Buy | $2,875 → $2,625 | $7.43 | +35,229.74% | 4 | Mar 17, 2021 | |
| SLDB Solid Biosciences | Maintains: Buy | $188 → $300 | $3.45 | +8,608.27% | 5 | Mar 16, 2021 | |
| PASG Passage Bio | Maintains: Buy | $36 → $45 | $0.39 | +11,558.03% | 3 | Mar 8, 2021 | |
| MCRB Seres Therapeutics | Upgrades: Buy | $28 → $30 | $0.68 | +4,336.56% | 2 | Mar 5, 2021 | |
| QURE uniQure | Maintains: Buy | $85 → $100 | $9.91 | +909.08% | 4 | Mar 2, 2021 | |
| SYBX Synlogic | Maintains: Buy | $75 → $150 | $1.22 | +12,195.08% | 2 | Jan 13, 2021 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | $53 → $50 | $3.25 | +1,438.46% | 3 | Oct 6, 2020 | |
| IMVT Immunovant | Maintains: Buy | $35 → $45 | $15.20 | +196.05% | 3 | Aug 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $115 | $174.58 | -34.13% | 2 | Aug 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $73 → $100 | $33.14 | +201.75% | 1 | Jul 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $95 | $27.16 | +249.78% | 2 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 → $15 | $7.95 | +88.68% | 4 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $130 | $6.76 | +1,823.08% | 4 | Jul 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $100 | $1.41 | +6,992.20% | 6 | Mar 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $2.5 → $2 | $541.20 | -99.63% | 2 | Jan 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $7.86 | - | 3 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $300 → $350 | $617.00 | -43.27% | 6 | Dec 12, 2016 |
Adverum Biotechnologies
Apr 29, 2021
Downgrades: Neutral
Price Target: $200 → $50
Current: $3.83
Upside: +1,205.48%
Taysha Gene Therapies
Apr 13, 2021
Maintains: Buy
Price Target: $60 → $68
Current: $1.27
Upside: +5,235.97%
Forte Biosciences
Mar 17, 2021
Maintains: Buy
Price Target: $2,875 → $2,625
Current: $7.43
Upside: +35,229.74%
Solid Biosciences
Mar 16, 2021
Maintains: Buy
Price Target: $188 → $300
Current: $3.45
Upside: +8,608.27%
Passage Bio
Mar 8, 2021
Maintains: Buy
Price Target: $36 → $45
Current: $0.39
Upside: +11,558.03%
Seres Therapeutics
Mar 5, 2021
Upgrades: Buy
Price Target: $28 → $30
Current: $0.68
Upside: +4,336.56%
uniQure
Mar 2, 2021
Maintains: Buy
Price Target: $85 → $100
Current: $9.91
Upside: +909.08%
Synlogic
Jan 13, 2021
Maintains: Buy
Price Target: $75 → $150
Current: $1.22
Upside: +12,195.08%
Iovance Biotherapeutics
Oct 6, 2020
Maintains: Buy
Price Target: $53 → $50
Current: $3.25
Upside: +1,438.46%
Immunovant
Aug 25, 2020
Maintains: Buy
Price Target: $35 → $45
Current: $15.20
Upside: +196.05%
Aug 19, 2020
Maintains: Buy
Price Target: $100 → $115
Current: $174.58
Upside: -34.13%
Jul 28, 2020
Maintains: Buy
Price Target: $73 → $100
Current: $33.14
Upside: +201.75%
Jul 15, 2020
Maintains: Buy
Price Target: $84 → $95
Current: $27.16
Upside: +249.78%
Aug 17, 2018
Downgrades: Neutral
Price Target: $19 → $15
Current: $7.95
Upside: +88.68%
Jul 16, 2018
Maintains: Buy
Price Target: $90 → $130
Current: $6.76
Upside: +1,823.08%
Mar 27, 2018
Maintains: Neutral
Price Target: $75 → $100
Current: $1.41
Upside: +6,992.20%
Jan 10, 2018
Upgrades: Neutral
Price Target: $2.5 → $2
Current: $541.20
Upside: -99.63%
Nov 10, 2017
Upgrades: Buy
Price Target: n/a
Current: $7.86
Upside: -
Dec 12, 2016
Upgrades: Neutral
Price Target: $300 → $350
Current: $617.00
Upside: -43.27%